Eisai Company Ltd (OP: ESALF )
64.97 +0.97 (+1.52%) Streaming Delayed Price Updated: 12:47 PM EDT, May 26, 2023 Add to My Watchlist
Headline News about Eisai Company Ltd
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid...
The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
August 03, 2022
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
March 15, 2022
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following